Intec Pharma Ltd.

JERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on Intec’s website, by selecting “Investors” and then “Financials” and “SEC Filings”. You may request a copy of the Company’s Form 10-K, at no cost to you, by writing to the Chief Financial Officer of the Company at 12 Hartom Street, Har Hotzvim, Jerusalem 9777512, Israel or by calling the Company at +972 (2) 586 4657. About Intec Pharma Ltd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. For more information, visit . Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website. No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. Additional Information about the Proposed Merger and Where to Find It In connection with the proposed merger between Intec Pharma and Decoy Biosystems, Intec Pharma will Registration Statement on Form S-4, which will include a document that serves as a proxy statement and prospectus of Intec Pharma and Intec Pharma plans to documents regarding the proposed merger with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHAREHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Intec Pharma’s and Decoy Biosystems’ shareholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC’s website at The documents filed by Intec with the SEC may also be obtained free of charge from the Company by requesting them by mail at Intec Pharma Ltd., 12 Hartom Street, Har Hotzvim, Jerusalem 9777512, Israel. Participants in the Solicitation Intec Pharma and its respective directors and executive officers and other members of management and employees and certain of their respective significant shareholders may be deemed to be participants in the solicitation of proxies from Intec shareholders in respect of the proposed merger. Information about the Intec Pharma’s directors and executive officers is available in Intec’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 16, 2021. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Intec Pharma as indicated above. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies, plans and prospects. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan“, “may“, “should“, “could“, “might“, “seek“, “target“, “will”, “project“, “forecast“, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Decoy’s future plans and expected timeline of its development pipeline and our expected timing of completion of the merger. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: risks associated with Intec Pharma’s and Decoy’s ability to obtain the shareholder approval required to consummate the proposed merger and the timing of the closing of the proposed merger, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed merger will not occur; risks related to the ability to consummate certain closing conditions including the pre-closing financing and the disposition of the Accordion Pill business, the occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement; the outcome of any legal proceedings that may be instituted against Intec Pharma or Decoy following the announcement of the merger agreement and the transactions contemplated therein; unanticipated difficulties or expenditures relating to the proposed merger, the response of business partners and competitors to the announcement of the proposed merger, and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed merger; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement or could otherwise cause the transaction to fail to close; the inability to list the merger shares on Nasdaq or maintain the listing of the combined company’s shares of common stock on Nasdaq following the proposed merger; the ability to recognize the anticipated benefits of the proposed merger. Risks and uncertainties relating to Decoy that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but not limited to: Decoy’s plans to develop and potentially commercialize its technology, the timing and cost of Decoy’s planned investigational new drug application and any clinical trials, the completion and receiving favorable results in any clinical trials, Decoy’s ability to obtain and maintain regulatory approval of any product candidate, Decoy’s ability to protect and maintain its intellectual property and licensing arrangements, Decoy’s ability to develop, manufacture and commercialize its product candidates, the risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation, and Decoy’s estimates regarding future revenue, expenses capital requirements and the need for additional financing following the merger. These risks, as well as other risks and uncertainties associated with the merger, will be discussed in the proxy statement/prospectus that will be included in the registration statement on Form S-4 to be filed with the SEC in connection with the merger. Additional risks and uncertainties are identified and discussed under the heading “Risk Factors” in Intec’s Annual Report and other period filings with the SEC. All forward-looking statements speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included in this presentation. Neither Intec nor Decoy undertake any obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law. Intec Pharma Investor Contact: Will O'Connor Stern IR +1 212-362-1200 will@sternir.com

At the two-year mark, Roche’s Evrysdi (risdiplam) either maintained or improved motor function from a one-year check-up in patients aged 2 to 25 with Types 2 or 3 spinal muscular atrophy, the Swiss drugmaker said Tuesday. Even better, Evrysdi showed no new long-term safety signals, and patients in the second year of treatment actually posted fewer severe side effects than in the first year, Roche said. The SUNFISH Part 2 study continues an initial one-year study for Types 2 and 3 SMA for Evrysdi, which snared an FDA approval back in August. In addition to studies in that setting, Roche is looking at Evrysdi follow-ups in Type 1 SMA as well as in patients who have received a prior SMA therapy prior to Evrysdi and in infants. “These encouraging results confirm that the efficacy and safety of Evrysdi in people with Type 2 and Type 3 SMA can be sustained over time,” Roche’s CMO Levi Garraway said in a statement. “Therefore, these findings further highlight the potential longer-term benefit this first-of-its-kind medicine can have for people of varying ages and levels of SMA disease severity.” — Kyle Blankenship What a year it’s been for llama researchers. The Belgium-based biotech ExeVir has closed a $50 million Series A round to advance development of its llama-derived antibodies for the treatment and prevention of Covid-19. ExeVir will use the financing to launch a global Phase Ib/II clinical trial of lead compound XVR011 that is scheduled to start “shortly,” the company said. “In only 9 months from set up, ExeVir has made fantastic progress in the development of lead compound XVR011 which is now ready to move into clinical development,” ExeVir chairman Philippe Monteyne said in a statement. “We are proud that Belgium is at the forefront of international efforts in cutting-edge research, innovation and science.” The Series A comes after the research team, in collaboration with the NIH, engineered a llama antibody to block the novel coronavirus last May. Some animals, like llamas, produce smaller antibodies called nanobodies that can potentially provide the foundation for inhaled Covid-19 therapeutics. Tuesday’s financing was led by Fund+ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, and new investors SRIW, Noshaq, Vives IUF, SambrInvest also participated, as well as several Belgian family offices. — Max Gelman Israel-based Intec Pharma is dipping its toes in immuno-oncology through a reverse merger with the preclinical startup Decoy Biosystems. $NTEC shares surged 87% in premarket trading after the companies announced the merger on Monday. On Tuesday morning, they were down 10.9%, pricing around $5.31 apiece. Decoy brings with it a “robust” immunotherapy pipeline, CEO Jeffrey Meckler said in a statement. The company says it will advance its platform to battle “a variety of tumor types and chronic viral infections.” It plans to file an IND in the second half of this year, and initiate a Phase I trial in 2022 targeting solid tumors and lymphomas. “Decoy’s bacteria-based platform is a novel modality which has the potential to dramatically change how we treat cancer and chronic viral diseases,” said Roger Pomerantz, who will become the combined company’s board chair. Former Decoy stockholders are expected to own about 75% of the combined company, while Intec shareholders will take about 25%. — Nicole DeFeudis

Summary Intec Pharma Ltd Intec Pharma is a biopharmaceutical company that offers delivery solutions for drugs. The company's pipeline products include drug indications for Parkinson's disease, insomnia and other diseases. Its proprietary gastro retentive formulation, offers a drug delivery solution to drugs that have poor solubility, poor colonic absorption or act locally in upper gastrointestinal part. Intec Pharma offers products for various therapeutic areas including the central nervous system, the cardiovascular system, and gastrointestinal and infectious diseases. It has collaborations with pharmaceutical and biopharmaceutical companies. Intec Pharma is headquartered in Jerusalem, Israel. Intec Pharma Ltd NTEC Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.